BirchBioMed (BRBM) files second S-1 amendment for 30.9 million-share Nasdaq IPO
As seen on the 24/7 Wall St. homepage on November 19, 2026.
BirchBioMed files second S-1 amendment for 30.9 million-share Nasdaq IPO
A second amendment moves the clinical-stage scarring and autoimmune developer closer to pricing, with 30.9 million shares lined up for a Nasdaq debut and Maxim Group running the book. Terms are still unpriced, so the next filing is the one that sets the entry point.
Continue ReadingShow less
BirchBioMed Inc. is a clinical-stage company focused on scarring and autoimmune conditions, and its second S-1 amendment signals that pricing is approaching. The filing locks in 30.9 million shares for a planned Nasdaq debut, with Maxim Group serving as the bookrunner.
A second amendment is a meaningful procedural milestone. It typically means the company has responded to SEC comments and is tightening the final terms before the registration is declared effective, putting the actual pricing event within reach.
Sponsored
What is still missing is the entry point. The offering remains unpriced, meaning the per-share range has not yet been set in a public filing. The next amendment, or a final prospectus, is what investors need to watch for before they can evaluate the deal on valuation grounds.
Until that price range lands, the 30.9 million share count is the most concrete sizing signal available. Investors tracking the clinical-stage biotech IPO pipeline should note this one is moving, even if the terms are not final.